Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Medtronic Resting Heart Bypass System · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Medtronic Resting Heart Bypass System | DEVICE | - |
Inclusion Criteria: * Consenting patients undergoing elective surgical coronary artery bypass grafting (CABG) with use of the cardiopulmonary bypass machine Exclusion Criteria: * Patients unable to provide written informed consent * Emergency CABG surgery * Concomitant CABG + Valvular surgery * O...
The Medtronic Resting Heart Bypass System is used for coronary artery bypass surgery. It is a device designed for use in heart surgery patients, specifically to facilitate bypass procedures while potentially avoiding the need for cardiopulmonary bypass. It is currently in Phase 1 clinical development.
The Medtronic Resting Heart Bypass System is developed by Medtronic plc, a medical device company traded on the New York Stock Exchange under the ticker symbol MDT. The system is being evaluated for use in coronary artery bypass surgery.
The Medtronic Resting Heart Bypass System is in Phase 1 clinical development. It is an investigational device, not yet approved for commercial use. One Phase 1 trial has been completed, involving 60 participants in Canada.
The Medtronic Resting Heart Bypass System has one completed clinical trial, registered as NCT00303641. The trial, titled 'Safety and Effectiveness of the Medtronic Resting Heart Bypass System in Heart Surgery Patients,' was a Phase 1 study with 60 participants in Canada.
The Medtronic Resting Heart Bypass System is not FDA approved. It is an investigational device currently in Phase 1 clinical development. A single Phase 1 trial has been completed, but the device has not yet received regulatory approval for commercial use.